Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KNSA NASDAQ:LQDA NASDAQ:SVA NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$35.71+0.6%$30.95$17.82▼$35.84$2.65B0.2429,216 shs328,234 shsLQDALiquidia Technologies$28.85+0.0%$20.43$8.75▼$29.94$2.48B0.223.02 million shs1.41 million shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.66M0.68N/AN/ATARSTarsus Pharmaceuticals$57.63+0.3%$47.31$28.07▼$59.76$2.43B0.81624,484 shs683,534 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International0.00%+6.63%+7.85%+18.13%+38.73%LQDALiquidia Technologies0.00%+4.23%+50.18%+59.04%+222.71%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%TARSTarsus Pharmaceuticals0.00%-1.62%+20.19%+31.22%+98.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$35.71+0.6%$30.95$17.82▼$35.84$2.65B0.2429,216 shs328,234 shsLQDALiquidia Technologies$28.85+0.0%$20.43$8.75▼$29.94$2.48B0.223.02 million shs1.41 million shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.66M0.68N/AN/ATARSTarsus Pharmaceuticals$57.63+0.3%$47.31$28.07▼$59.76$2.43B0.81624,484 shs683,534 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International0.00%+6.63%+7.85%+18.13%+38.73%LQDALiquidia Technologies0.00%+4.23%+50.18%+59.04%+222.71%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%TARSTarsus Pharmaceuticals0.00%-1.62%+20.19%+31.22%+98.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKNSAKiniksa Pharmaceuticals International 3.00Buy$41.1715.28% UpsideLQDALiquidia Technologies 3.00Buy$32.1111.30% UpsideSVASinovac Biotech 0.00N/AN/AN/ATARSTarsus Pharmaceuticals 2.83Moderate Buy$66.6715.68% UpsideCurrent Analyst Ratings BreakdownLatest SVA, KNSA, TARS, and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025LQDALiquidia TechnologiesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.008/13/2025LQDALiquidia TechnologiesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$33.00 ➝ $41.008/13/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $31.008/12/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $36.007/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $54.007/21/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.007/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $42.006/12/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$23.00 ➝ $25.006/11/2025LQDALiquidia TechnologiesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $23.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKNSAKiniksa Pharmaceuticals International$423.24M6.25N/AN/A$6.60 per share5.41LQDALiquidia Technologies$19.32M128.54N/AN/A$0.91 per share31.70SVASinovac Biotech$448.27M1.44$0.17 per share38.95$120.83 per share0.05TARSTarsus Pharmaceuticals$182.95M13.30N/AN/A$5.87 per share9.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKNSAKiniksa Pharmaceuticals International-$43.19M$0.04892.97142.84N/A0.90%1.05%0.80%11/4/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.70N/AN/AN/A-732.17%-232.96%-60.81%11/12/2025 (Estimated)SVASinovac Biotech-$99.92MN/A0.00∞N/AN/AN/AN/AN/ATARSTarsus Pharmaceuticals-$115.55M-$2.33N/AN/AN/A-31.13%-32.36%-21.04%11/12/2025 (Estimated)Latest SVA, KNSA, TARS, and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025LQDALiquidia Technologies-$0.43-$0.49-$0.06-$0.49$3.90 million$8.84 million8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 million7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ALQDALiquidia TechnologiesN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKNSAKiniksa Pharmaceuticals InternationalN/A3.573.16LQDALiquidia Technologies9.842.492.41SVASinovac BiotechN/AN/AN/ATARSTarsus Pharmaceuticals0.225.265.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKNSAKiniksa Pharmaceuticals International53.95%LQDALiquidia Technologies64.54%SVASinovac BiotechN/ATARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipKNSAKiniksa Pharmaceuticals International53.48%LQDALiquidia Technologies26.50%SVASinovac Biotech12.79%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableLQDALiquidia Technologies5086.09 million63.28 millionOptionableSVASinovac Biotech3,26199.64 million86.89 millionOptionableTARSTarsus Pharmaceuticals5042.21 million38.43 millionOptionableSVA, KNSA, TARS, and LQDA HeadlinesRecent News About These CompaniesCormorant Asset Management LP Sells 100,000 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6 at 7:45 AM | marketbeat.comCutter Capital Management LP Acquires 92,500 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6 at 7:35 AM | marketbeat.comAlly Bridge Group NY LLC Sells 45,212 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 5 at 6:53 AM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Time to Buy?September 4 at 12:32 PM | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Frazier Life Sciences Management L.P.September 4 at 6:50 AM | marketbeat.comNorthern Trust Corp Grows Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 3, 2025 | marketbeat.comGhisallo Capital Management LLC Acquires New Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 2, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Position Increased by Paradigm Biocapital Advisors LPSeptember 2, 2025 | marketbeat.com5,284 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by FORA Capital LLCSeptember 1, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Invests $36.88 Million in Tarsus Pharmaceuticals, Inc. $TARSAugust 31, 2025 | marketbeat.comWellington Management Group LLP Trims Stock Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 31, 2025 | marketbeat.comJump Financial LLC Takes $2.51 Million Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 29, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.com16,020 Shares in Tarsus Pharmaceuticals, Inc. $TARS Acquired by Quantbot Technologies LPAugust 27, 2025 | marketbeat.com3 Biotech Catalysts Present Major Opportunity (TARS)...August 25, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Aberdeen Group plcAugust 24, 2025 | marketbeat.comNuveen LLC Purchases New Shares in Tarsus Pharmaceuticals, Inc. $TARSAugust 24, 2025 | marketbeat.comVanguard Group Inc. Increases Stock Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 24, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Atika Capital Management LLCAugust 23, 2025 | marketbeat.comRussell Investments Group Ltd. Acquires 132,450 Shares of Tarsus Pharmaceuticals, Inc. $TARSAugust 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVA, KNSA, TARS, and LQDA Company DescriptionsKiniksa Pharmaceuticals International NASDAQ:KNSA$35.71 +0.20 (+0.56%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$35.69 -0.02 (-0.06%) As of 09/5/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Liquidia Technologies NASDAQ:LQDA$28.85 +0.01 (+0.03%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$28.89 +0.04 (+0.14%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Sinovac Biotech NASDAQ:SVASinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.Tarsus Pharmaceuticals NASDAQ:TARS$57.63 +0.20 (+0.35%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$57.62 -0.01 (-0.01%) As of 09/5/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
